Shionogi & Co Ltd

Shionogi’s 21% stake in ViiV Healthcare boosts its HIV portfolio, unlocking long‑acting therapies and cost‑efficient manufacturing for a high‑barrier market.

Shionogi’s 2025 results show a strong operating margin driven by a broad‑spectrum antibacterial partnership, with strategic IP, market‑access plans, and M&A options poised to sustain growth amid patent cliffs and fierce competition.

Shionogi partners with Cumulus Neuroscience to boost cognitive drug trials while expanding its antifungal portfolio, positioning itself for growth in high‑potential markets.

Shionogi’s $120 M stake in ViiV Healthcare unlocks global HIV therapy growth, leveraging Japanese distribution to boost sales and secure early access to next‑generation ARTs.

Shionogi & Co., Ltd. remains a stable Japanese pharma firm with strong R&D in antibiotics, rare‑disease drugs, and vaccines, poised for growth amid U.S.–Japan supply‑chain collaboration.

Shionogi & Co.: Japan’s quietly stable pharma firm prioritises long‑term R&D, low leverage, and PMDA‑friendly compliance—offering a value‑investor‑friendly platform for future breakthroughs.

Shionogi expands ALS R&D and global reach, partnering with Salubritas and securing Radicava® rights—boosting science, market share, and investor confidence.

Shionogi & Co. maintains a stable financial position, with a steady stock price and moderate valuation, solidifying its position as a stalwart in the pharmaceutical industry.

Shionogi & Co Ltd’s stable stock price reflects investor optimism about the company’s prospects in developing treatments for interstitial cystitis, a growing market with modest growth expected.

Shionogi & Co., a Japanese pharmaceutical company, has released its 9-month financial results, highlighting key metrics such as a closing price of 2,547 JPY and a price-to-earnings ratio of 12.09.